Lupin’s stock price is in focus as Nomura maintains a buy rating, setting a target price of ₹2,350, implying an upside of 15.82% from the current market price (CMP) of ₹2,029.00.
The brokerage is positive on Lupin’s March 7, 2025, launch of generic Xarelto (gXarelto) 2.5mg in the US, following final approval from the USFDA. The drug has annual sales of $446 million (IQVIA), but Nomura estimates the market size at $125 million at the manufacturer price. The overall Xarelto market, including other strengths, is valued at $2.4 billion in the US. Lupin is also one of four first filers for this strength, and the launch was slightly ahead of expectations.
Disclaimer: The views and investment recommendations in this article are sourced from brokerage reports. Business Upturn does not provide investment advice. Readers should consult financial experts before making any investment decisions.
